Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Discovery Grants Program - Individual

University of Waterloo

$67,000.00

Cyclic Peptide Antibiotics: Total Synthesis and Mechanism of Action Studies

FY 2024-25

Summary
One of the most important advances in modern medicine was the discovery of antibiotics. Unfortunately, bacteria have developed or are rapidly developing resistance to many of the common antibiotics that physicians rely upon on a daily basis to treat infection. The World Health Organization has identified multidrug resistant (MDR) bacteria as one of the most important threats to human health. Despite the urgency of the situation, pharmaceutical companies are reluctant to develop new antibiotics due to their relatively low return on investment. Therefore, academic scientists must step up to the plate to develop the next generation of antibiotics. This research proposal deals with three antibiotics: CDA3a, LL-0341-beta1, and turnercyclamycin. These three antibiotics are part of a class of antibiotics called cyclic peptide antibiotics. How they work, or what we call their `mechanism of action' (MoA), is not known. They are not used in the clinic; however, they have promising antibacterial properties that justifies investigations into their potential as lead structures for the development of antibiotics that are active against MDR bacteria. The objectives of this proposal are two-fold. One is to develop the first chemical syntheses of these complex peptides. By knowing how to make these molecules, we will be able to make modified versions of these antibiotics. These modified versions will enable us to more readily achieve our second objective which is to elucidate the mechanism of action of these antibiotics. Using a multidisciplinary approach that involves chemical synthesis, biophysical studies and cell and microbiological techniques, we will determine the molecular targets of these antibiotics and how their interaction with these targets translates into antimicrobial activity. The long-term goal of this research is to use the experience we obtained from our synthetic studies and the information gleaned from our mechanistic studies to develop antibiotics with superiour properties such as reduced toxicity and good activity against MDR bacteria.
Program
Discovery Grants Program - Individual
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
RGPIN-2023-03387
Name nom
Taylor, Scott
Department département
Chemistry
Organization id
33
Institution établissement
University of Waterloo
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2024
Competition year année de concours
2023
Award amount
67000
Program id
RGPIN
Program name en
Discovery Grants Program - Individual
Program name fr
Programme de subventions à la découverte - individuelles
Group en
DISCOVERY RESEARCH
Group fr
RECHERCHE AXÉE SUR LA DÉCOUVERTE
Committee code
1504
Committee name en
Chemistry
Committee name fr
Chimie
Area of application code
1211
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Medical and health sciences
Area of application fr
Sciences médicales et de la santé
Research subject code
3700
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Organic chemistry
Research subject fr
Chimie organique
Field of research list names en
Not available
Field of research list names fr
Non disponible
Socioeconomic objective list names en
Not available
Socioeconomic objective list names fr
Non disponible
Application title
Cyclic Peptide Antibiotics: Total Synthesis and Mechanism of Action Studies
Keywords
organic synthesis; antibiotics; cyclic peptides; mechanisms of antibiotics; uncommon amino acids
Application summary
One of the most important advances in modern medicine was the discovery of antibiotics. Unfortunately, bacteria have developed or are rapidly developing resistance to many of the common antibiotics that physicians rely upon on a daily basis to treat infection. The World Health Organization has identified multidrug resistant (MDR) bacteria as one of the most important threats to human health. Despite the urgency of the situation, pharmaceutical companies are reluctant to develop new antibiotics due to their relatively low return on investment. Therefore, academic scientists must step up to the plate to develop the next generation of antibiotics. This research proposal deals with three antibiotics: CDA3a, LL-0341-beta1, and turnercyclamycin. These three antibiotics are part of a class of antibiotics called cyclic peptide antibiotics. How they work, or what we call their `mechanism of action' (MoA), is not known. They are not used in the clinic; however, they have promising antibacterial properties that justifies investigations into their potential as lead structures for the development of antibiotics that are active against MDR bacteria. The objectives of this proposal are two-fold. One is to develop the first chemical syntheses of these complex peptides. By knowing how to make these molecules, we will be able to make modified versions of these antibiotics. These modified versions will enable us to more readily achieve our second objective which is to elucidate the mechanism of action of these antibiotics. Using a multidisciplinary approach that involves chemical synthesis, biophysical studies and cell and microbiological techniques, we will determine the molecular targets of these antibiotics and how their interaction with these targets translates into antimicrobial activity. The long-term goal of this research is to use the experience we obtained from our synthetic studies and the information gleaned from our mechanistic studies to develop antibiotics with superiour properties such as reduced toxicity and good activity against MDR bacteria.